Editorial: Advancements in HPV research: integrating diagnostics, vaccination, and women’s health

Abstract

Human papillomavirus (HPV) infection leading to cervical cancer remains one of the most urgent public health challenges worldwide. In 2022 alone, there were an estimated 662,301 new cervical cancer cases and 348,874 deaths globally, with the burden heavily affecting low- and middle-income countries (LMICs) where access to prevention, screening, and treatment remains limited (1, 2). Persistent infection with high-risk HPV genotypes, especially types 16 and 18, underpins nearly all cases of cervical cancer, causing over 300,000 deaths each year (3). Despite significant scientific advances in HPV diagnostics and vaccine development over the past two decades, translating these innovations into equitable healthcare practices remains a major global challenge (4). A clearer understanding of how best to deliver evidence-based interventions in real-world settings is crucial to bridging the gap between research and actual health outcomes, especially in low-resource settings where vaccination uptake, screening coverage, sociocultural barriers, and health system limitations continue to pose challenges.